Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
Cassava Sciences (NASDAQ: SAVA) announced key leadership changes in its clinical development team. Dr. James W. Kupiec, Chief Medical Officer, will retire effective May 9, 2025, after completing the company's Alzheimer's disease clinical trial program. Dr. Jack Moore has been appointed as Senior Vice President of Clinical Development, effective April 28, 2025.
Dr. Moore will focus on advancing the clinical evaluation of simufilam for new potential indications, including tuberous sclerosis complex (TSC)-related epilepsy. He brings extensive experience in medical affairs and clinical development from leading global pharmaceutical companies, particularly in CNS disorders.
Cassava Sciences (NASDAQ: SAVA) ha annunciato importanti cambiamenti nella sua squadra di sviluppo clinico. Il dott. James W. Kupiec, Chief Medical Officer, andrà in pensione a partire dal 9 maggio 2025, dopo aver completato il programma di studi clinici sull'Alzheimer dell'azienda. Il dott. Jack Moore è stato nominato Senior Vice President dello Sviluppo Clinico, con decorrenza dal 28 aprile 2025.
Il dott. Moore si concentrerà sull'avanzamento della valutazione clinica di simufilam per nuove potenziali indicazioni, tra cui l'epilessia correlata alla sclerosi tuberosa (TSC). Porta con sé una vasta esperienza in affari medici e sviluppo clinico, maturata in importanti aziende farmaceutiche globali, soprattutto nel campo dei disturbi del sistema nervoso centrale.
Cassava Sciences (NASDAQ: SAVA) anunció cambios clave en su equipo de desarrollo clínico. El Dr. James W. Kupiec, Director Médico, se retirará a partir del 9 de mayo de 2025, tras completar el programa de ensayos clínicos de la empresa sobre la enfermedad de Alzheimer. El Dr. Jack Moore ha sido nombrado Vicepresidente Senior de Desarrollo Clínico, con efecto desde el 28 de abril de 2025.
El Dr. Moore se centrará en avanzar en la evaluación clínica de simufilam para nuevas indicaciones potenciales, incluyendo la epilepsia relacionada con el complejo de esclerosis tuberosa (TSC). Aporta una amplia experiencia en asuntos médicos y desarrollo clínico, adquirida en compañías farmacéuticas globales líderes, especialmente en trastornos del sistema nervioso central.
Cassava Sciences (NASDAQ: SAVA)는 임상 개발 팀의 주요 리더십 변화를 발표했습니다. 제임스 W. 쿠피에크 박사(Chief Medical Officer)는 2025년 5월 9일부로 은퇴할 예정이며, 회사의 알츠하이머병 임상 시험 프로그램을 마무리할 예정입니다. 잭 무어 박사가 2025년 4월 28일부로 임상 개발 수석 부사장으로 임명되었습니다.
무어 박사는 결절성 경화증(TSC) 관련 간질을 포함한 새로운 적응증에 대한 시무필람의 임상 평가를 진전시키는 데 주력할 것입니다. 그는 중추신경계 질환 분야를 중심으로 세계적인 제약사에서 의학 업무 및 임상 개발 경험을 풍부하게 쌓아왔습니다.
Cassava Sciences (NASDAQ: SAVA) a annoncé des changements clés dans son équipe de développement clinique. Le Dr James W. Kupiec, Chief Medical Officer, prendra sa retraite à compter du 9 mai 2025, après avoir terminé le programme d'essais cliniques de la société sur la maladie d'Alzheimer. Le Dr Jack Moore a été nommé Senior Vice President du développement clinique, à compter du 28 avril 2025.
Le Dr Moore se concentrera sur l'avancement de l'évaluation clinique de simufilam pour de nouvelles indications potentielles, y compris l'épilepsie liée au complexe de sclérose tubéreuse (TSC). Il apporte une vaste expérience en affaires médicales et développement clinique acquise dans des entreprises pharmaceutiques mondiales de premier plan, notamment dans les troubles du système nerveux central.
Cassava Sciences (NASDAQ: SAVA) gab bedeutende Führungswechsel in seinem klinischen Entwicklungsteam bekannt. Dr. James W. Kupiec, Chief Medical Officer, wird zum 9. Mai 2025 in den Ruhestand treten, nachdem er das klinische Studienprogramm des Unternehmens zur Alzheimer-Krankheit abgeschlossen hat. Dr. Jack Moore wurde zum Senior Vice President für klinische Entwicklung ernannt, mit Wirkung zum 28. April 2025.
Dr. Moore wird sich darauf konzentrieren, die klinische Bewertung von simufilam für neue potenzielle Indikationen voranzutreiben, einschließlich der epileptischen Erkrankungen im Zusammenhang mit dem tuberösen Sklerose-Komplex (TSC). Er bringt umfangreiche Erfahrung in medizinischen Angelegenheiten und klinischer Entwicklung aus führenden globalen Pharmaunternehmen mit, insbesondere im Bereich der ZNS-Erkrankungen.
- Successfully completed Alzheimer's disease clinical trial program
- Strategic expansion into TSC-related epilepsy indication
- Strengthened clinical development team with experienced CNS expert
- Loss of experienced Chief Medical Officer
- Transition period in clinical leadership may cause temporary delays
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice President, Clinical Development, reporting to Rick Barry, Chief Executive Officer.
“The entire Cassava team is grateful for Jim’s service as our Chief Medical Officer. He is retiring after a notable career of exemplary work, with exceptional expertise in Alzheimer’s disease drug development. Thanks to Jim’s attention to patient care and his deep credibility in the scientific community, Cassava completed a high-quality clinical trial program in Alzheimer’s disease that was carried out with respect for the dignity of patients and their caregivers. We wish Jim a happy and fulfilling retirement,” said Rick Barry, President and Chief Executive Officer of Cassava.
Dr. Moore joins Cassava as Senior Vice President, Clinical Development, effective April 28, 2025. He will be responsible for advancing the clinical evaluation of simufilam in new potential indications, including TSC. Dr. Moore will build on an established track record of working in leading global pharmaceutical companies to advance novel compounds for the treatment of CNS disorders.
“As we formulate our strategy going forward, we are pleased to have Jack on board. He brings broad medical affairs and clinical development expertise, plus extensive experience working with study sites and patient advocacy groups. These skills will be invaluable to Cassava as we take the next steps in our TSC program, identify potential clinical collaborators and study sites, and explore additional potential applications,” commented Mr. Barry.
“I am eager to contribute my clinical development expertise to Cassava’s emerging program for simufilam in TSC and other applications,” said Dr. Jack Moore, SVP, Clinical Development of Cassava.
About Jack Moore, PhD
Jack Moore is an accomplished biopharmaceutical executive with extensive drug development expertise in CNS and neurodegenerative diseases including Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and other neuro-immunologic and oncologic disorders. He has a history of building and executing clinical development strategies and publication plans, as well as engaging with key opinion leaders, advisory boards, patient advocates, and medical communities in established and rare clinical indications across multiple drug modalities. Most recently, Dr. Moore was Vice President, Head of Global Medical Affairs at Alector Inc. Prior to that, Dr. Moore held clinical and medical affairs leadership roles of increasing responsibility at global pharmaceutical companies including Janssen Pharmaceutica, Novartis Pharmaceuticals Corporation, and Celgene Corporation, a subsidiary of Bristol-Myers Squibb Company.
Dr. Moore earned his Doctor of Philosophy in Neuroscience at the University of North Texas, and he was a Post-Doctoral Research Fellow at the University of Texas at Southwestern Medical Center at Dallas. He earned his Master of Science in Physiology at the University of North Texas, and his Bachelor of Science in Biology at Texas State University.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders such as tuberous sclerosis complex (TSC)-related epilepsy. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. The Company is based in Austin, Texas.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com
Media
media@cassavasciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
IR@cassavasciences.com
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements that include but are not limited to statements regarding: our plans to conduct preclinical studies of simufilam relating to seizures in TSC, the potential for simufilam as a treatment for TSC-related epilepsy and other indications, the timing of anticipated milestones, and management retirees or appointments. These statements may be identified by words such as “anticipate”, “before,” “believe”, “could”, “expect”, “forecast”, “intend”, “may”, “pending,” “plan”, “possible”, “potential”, “prepares for,” “will”, and other words and terms of similar meaning.
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to efficiently discontinue the Company’s Alzheimer’s disease development program, the ability to advance preclinical studies related to TSC-related epilepsy, and other risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at www.sec.gov.
All of our pharmaceutical assets under development are investigational product candidates. They have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
We are in the business of new drug discovery, development and commercialization. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery, development and commercialization, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
FAQ
What leadership changes did Cassava Sciences (SAVA) announce in April 2025?
What will be Dr. Jack Moore's role at Cassava Sciences (SAVA)?
What therapeutic areas is Cassava Sciences (SAVA) currently focusing on?
What was Dr. Kupiec's main achievement at Cassava Sciences (SAVA)?
